Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
09:09:42 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:TGTX - TG THERAPEUTICS INC - http://www.tgtherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
TGTX - Q0.113.60·14.000.113.9911.816426    35.67  6.4608:52:17Apr 1815 min RT 2¢

Recent Trades - Last 10 of 26
Time ETExPriceChangeVolume
08:52:17Q14.000.012,500
08:46:58Q14.000.012,000
08:33:40Q13.90-0.09649
08:30:03Q14.000.011
08:30:03Q14.020.0310
08:30:03Q14.020.035
08:30:03Q14.020.035
08:29:08Q14.030.045
08:24:48Q14.180.191
08:02:12Q14.150.165

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-18 07:30U:TGTXNews ReleaseTG Therapeutics Announces Additional Data Presentations for BRIUMVI(TM) (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
2024-04-18 07:00U:TGTXNews ReleaseTG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
2024-04-15 07:30U:TGTXNews ReleaseTG Therapeutics Announces Presentation of Data for BRIUMVI(TM) (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
2024-03-08 07:30U:TGTXNews ReleaseTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI(TM) (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
2024-03-01 07:30U:TGTXNews ReleaseTG Therapeutics Announces Presentation of Data for BRIUMVI(TM) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
2024-02-28 07:00U:TGTXNews ReleaseTG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
2024-02-27 07:30U:TGTXNews ReleaseTG Therapeutics Announces Issuance of Additional Patents for BRIUMVI(TM) (ublituximab-xiiy)
2024-02-26 07:00U:TGTXNews ReleaseTG Therapeutics Announces European Launch of BRIUMVI(TM) (ublituximab-xiiy)
2024-02-23 07:30U:TGTXNews ReleaseTG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
2024-02-20 07:30U:TGTXNews ReleaseTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI ‚ ® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
2024-01-10 07:00U:TGTXNews ReleaseTG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
2024-01-09 07:00U:TGTXNews ReleaseTG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision ¢ € ™s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases
2024-01-05 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-27 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
2023-11-03 07:30U:TGTXNews ReleaseTG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference
2023-11-01 07:30U:TGTXNews ReleaseTG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
2023-10-30 07:30U:TGTXNews ReleaseTG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update
2023-10-12 11:00U:TGTXNews ReleaseTG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
2023-10-11 10:30U:TGTXNews ReleaseTG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
2023-10-02 07:30U:TGTXNews ReleaseTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting